Tango Therapeutics (TNGX) Competitors $7.23 -0.22 (-3.01%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. MOR, IMVT, XENE, VKTX, OGN, KNSA, NAMS, BHC, GMTX, and CGONShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include MorphoSys (MOR), Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors MorphoSys Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology Tango Therapeutics (NASDAQ:TNGX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Which has better valuation and earnings, TNGX or MOR? Tango Therapeutics has higher earnings, but lower revenue than MorphoSys. Tango Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M19.19-$130.30M-$1.33-5.46MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more risk and volatility, TNGX or MOR? Tango Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Do analysts recommend TNGX or MOR? Tango Therapeutics currently has a consensus target price of $10.50, indicating a potential upside of 44.69%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tango Therapeutics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TNGX or MOR more profitable? MorphoSys has a net margin of -226.79% compared to Tango Therapeutics' net margin of -599.11%. Tango Therapeutics' return on equity of -79.72% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-599.11% -79.72% -49.30% MorphoSys -226.79%-694.31%-22.55% Does the media prefer TNGX or MOR? In the previous week, Tango Therapeutics had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Tango Therapeutics and 0 mentions for MorphoSys. Tango Therapeutics' average media sentiment score of 0.75 beat MorphoSys' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tango Therapeutics Positive MorphoSys Neutral Do institutionals and insiders have more ownership in TNGX or MOR? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 7.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTango Therapeutics beats MorphoSys on 12 of the 16 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$808.30M$3.15B$5.76B$10.50BDividend YieldN/A2.36%5.61%4.58%P/E Ratio-5.4621.0376.6326.90Price / Sales19.19451.34551.24127.98Price / CashN/A44.8325.8131.15Price / Book3.909.8413.666.52Net Income-$130.30M-$52.73M$3.29B$271.58M7 Day Performance-1.27%3.65%2.40%3.67%1 Month Performance5.17%5.95%4.81%8.14%1 Year Performance-5.63%17.38%81.05%26.94% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.9013 of 5 stars$7.23-3.0%$10.50+45.3%-10.2%$804.97M$42.07M-5.4490MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant2.0344 of 5 stars$15.53-3.9%$33.60+116.4%-46.7%$2.82BN/A-5.45120Positive NewsXENEXenon Pharmaceuticals2.5476 of 5 stars$35.99-0.6%$53.30+48.1%-6.8%$2.79B$7.50M-10.14210Positive NewsVKTXViking Therapeutics4.4216 of 5 stars$24.08-2.9%$87.50+263.4%-62.8%$2.79BN/A-15.7420Analyst ForecastOGNOrganon & Co.4.5665 of 5 stars$10.39-2.5%$17.33+66.9%-45.7%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.5446 of 5 stars$36.56-1.5%$41.17+12.6%+40.7%$2.75B$423.24M914.23220Positive NewsNAMSNewAmsterdam Pharma3.1516 of 5 stars$24.12-0.3%$41.55+72.2%+69.9%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.6074 of 5 stars$7.17-1.2%$9.00+25.5%-15.0%$2.69B$9.86B27.5820,700Analyst UpgradeGMTXGemini TherapeuticsN/A$59.82-0.8%N/A+26.4%$2.59BN/A-59.8230CGONCG Oncology2.5558 of 5 stars$34.60+3.8%$53.91+55.8%-5.0%$2.54B$1.14M-19.5561Insider Trade Related Companies and Tools Related Companies MOR Competitors IMVT Competitors XENE Competitors VKTX Competitors OGN Competitors KNSA Competitors NAMS Competitors BHC Competitors GMTX Competitors CGON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
